Urteste SA (URT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Urteste SA (URT) has a cash flow conversion efficiency ratio of 0.441x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł9.55 Million ≈ $2.63 Million USD) by net assets (zł21.64 Million ≈ $5.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Urteste SA - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Urteste SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Urteste SA for a breakdown of total debt and financial obligations.
Urteste SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Urteste SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EAT WELL INVESTMENT GROUP
F:6BC0
|
N/A |
|
Vincit Group Oyj
HE:VINCIT
|
-0.010x |
|
Predictive Oncology Inc
NASDAQ:POAI
|
0.021x |
|
Prairie Provident Resources Inc
TO:PPR
|
0.195x |
|
Dignitana AB
ST:DIGN
|
-0.115x |
|
Salee Colour Public Company Limited
BK:COLOR
|
0.017x |
|
MyTech Group Bhd
KLSE:7692
|
0.134x |
|
Inovalis Real Estate Investment Trust
TO:INO-UN
|
0.021x |
Annual Cash Flow Conversion Efficiency for Urteste SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Urteste SA from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Urteste SA (URT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł24.11 Million ≈ $6.64 Million |
zł-5.47 Million ≈ $-1.50 Million |
-0.227x | -18.22% |
| 2023-12-31 | zł27.74 Million ≈ $7.64 Million |
zł-5.32 Million ≈ $-1.46 Million |
-0.192x | +71.57% |
| 2022-12-31 | zł5.62 Million ≈ $1.55 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.675x | -154.05% |
| 2021-12-31 | zł9.69 Million ≈ $2.67 Million |
zł-2.57 Million ≈ $-708.19K |
-0.266x | +73.22% |
| 2020-12-31 | zł1.37 Million ≈ $375.68K |
zł-1.35 Million ≈ $-372.56K |
-0.992x | -197.46% |
| 2019-12-31 | zł1.20 Million ≈ $328.95K |
zł-398.48K ≈ $-109.67K |
-0.333x | -- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.